Inozyme Pharma (NASDAQ: INZY)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-10 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.710 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Inozyme Pharma (NASDAQ: INZY) through any online brokerage.
Other companies in Inozyme Pharma’s space includes: AVEO Pharmaceuticals (NASDAQ:AVEO), Impel Pharmaceuticals (NASDAQ:IMPL), Ambrx Biopharma (NYSE:AMAM), Humanigen (NASDAQ:HGEN) and Fusion Pharmaceuticals (NASDAQ:FUSN).
The latest price target for Inozyme Pharma (NASDAQ: INZY) was reported by Jefferies on Thursday, May 26, 2022. The analyst firm set a price target for 5.00 expecting INZY to rise to within 12 months (a possible 25.94% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Inozyme Pharma (NASDAQ: INZY) is $3.97 last updated May 27, 2022, 8:00 PM UTC.
There are no upcoming dividends for Inozyme Pharma.
Inozyme Pharma’s Q2 earnings are confirmed for Wednesday, August 10, 2022.
There is no upcoming split for Inozyme Pharma.
Inozyme Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.